- Home
- CURR vs BIOA Comparison
CURR vs BIOA Comparison
Compare CURR & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- BIOA
- Stock Information
- Founded
- CURR 2013
- BIOA 2015
- Country
- CURR Singapore
- BIOA United States
- Employees
- CURR N/A
- BIOA N/A
- Industry
- CURR Business Services
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- CURR Consumer Discretionary
- BIOA Health Care
- Exchange
- CURR Nasdaq
- BIOA Nasdaq
- Market Cap
- CURR 151.4M
- BIOA 155.2M
- IPO Year
- CURR N/A
- BIOA 2024
- Fundamental
- Price
- CURR $1.70
- BIOA $4.55
- Analyst Decision
- CURR Strong Buy
- BIOA Hold
- Analyst Count
- CURR 1
- BIOA 4
- Target Price
- CURR $3.50
- BIOA $5.67
- AVG Volume (30 Days)
- CURR 591.8K
- BIOA 97.3K
- Earning Date
- CURR 08-04-2025
- BIOA 08-06-2025
- Dividend Yield
- CURR N/A
- BIOA N/A
- EPS Growth
- CURR N/A
- BIOA N/A
- EPS
- CURR N/A
- BIOA N/A
- Revenue
- CURR $41,092,419.00
- BIOA $3,863,000.00
- Revenue This Year
- CURR N/A
- BIOA N/A
- Revenue Next Year
- CURR $21.53
- BIOA N/A
- P/E Ratio
- CURR N/A
- BIOA N/A
- Revenue Growth
- CURR N/A
- BIOA N/A
- 52 Week Low
- CURR $0.33
- BIOA $2.88
- 52 Week High
- CURR $7.08
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- BIOA N/A
- Support Level
- CURR N/A
- BIOA N/A
- Resistance Level
- CURR N/A
- BIOA N/A
- Average True Range (ATR)
- CURR 0.00
- BIOA 0.00
- MACD
- CURR 0.00
- BIOA 0.00
- Stochastic Oscillator
- CURR 0.00
- BIOA 0.00
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.